Dry Eye

Systane iLux non-inferior to Lipiflow in change in meibomian gland score

Posted on

A single treatment of Systane iLux was non-inferior to Lipiflow Thermal pulsation system in change in meibomian gland score (MGS) up to 9 months in patients with evaporative dry eye disease (EDE), according to data presented at the 2021 ASCRS Annual Meeting.

In this prospective, randomized, assessor-masked, parallel group study, 188 patients with EDE were treated with either Systane iLux (Alcon) or LipiFlow (Johnson & Johnson Vision) and evaluated at baseline, treatment, 2 weeks, and months 1, 3, 6, 9, and 12. In each eye, 15 glands of the lower lid were graded from 0-3 (0 = no secretion, 1 = inspissated, 2 = cloudy, 3 = clear liquid).

Interim analyses were conducted at months 1, 3, 6, and 9 and found that non-inferiority of iLux compared to LipiFlow in change from baseline in MGS was achieved at each time point.

Tauber J, et al. Comparison between Systane Ilux and Lipiflow in the treatment of meibomian gland dysfunction (MGD): A 12-month, multicenter study. Presented at: 2021 ASCRS Annual Meeting.

Related Articles
Not All DED Patients Have Chronic Symptoms
Aug 02, 2021
Dry Eye Awareness Month: Focus on these 3 Goals
Jul 27, 2021
ALG-1007 topical eye drop meets primary, secondary endpoints for dry eye disease
Jul 24, 2021